Company intelligence / Profile preview
Arugula Sciences
Irving, Texas, United Statesarugulasciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Received FDA approval for Phase 1 clinical trials for two products: SIG001 (Signature Cord Prime™) for knee osteoarthritis and SIG002 (perinatal-derived secretome product) for big toe osteoarthritis. First participant for SIG002 was expected to be enrolled in February 2023.
- Therapeutic areas
- ImmunologyRheumatology
- Modalities
- Human perinatal tissue-based therapeuticsUmbilical Cord Mesenchymal Stem Cells (UC-MSC)Acellular technologies (Secretome)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Forte Orthopedic Research Institute
Beyond the preview
Go deeper on Arugula Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arugula Sciences.